Principal Financial Group Inc Ventyx Biosciences, Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$1.9 - $10.13 $115 - $617	-61 Reduced 0.46%	13,180 $72,000
Q4 2023 Feb 07, 2024	BUY	$2.08 - $31.18 $869 - $13,033	418 Added 3.26%	13,241 $32,000
Q3 2023 Nov 02, 2023	SELL	$29.8 - $40.3 $7,181 - $9,712	-241 Reduced 1.84%	12,823 $445,000
Q2 2023 Aug 07, 2023	BUY	$28.53 - $39.55 $59,485 - $82,461	2,085 Added 18.99%	13,064 $428,000
Q1 2023 May 09, 2023	SELL	$29.51 - $46.65 $17,824 - $28,176	-604 Reduced 5.21%	10,979 $367,000
Q4 2022 Feb 09, 2023	BUY	$24.16 - $36.38 $279,845 - $421,389	11,583 New	11,583 $379,000

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.